[Federal Register Volume 67, Number 81 (Friday, April 26, 2002)]
[Notices]
[Page 20827]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-10305]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 3, 2001, Isotec, 
Inc., 3858 Benner Road, Miamisburg, Ohio 45342, made application by 
renewal to the Drug Enforcement Administration (DEA) for registration 
as a bulk manufacturer of the basic classes of controlled substances 
listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
Aminorex (1585)............................  I
Methaqualone (2565)........................  I
Lysergic acid diethylamide (7315)..........  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
2, 5-Dimethoxyamphetamine (7396)...........  I
3,4-Methylenedioxyamphetamine..............  I
  (7400)...................................
3,4-Methyl-enedioxy-N-ethylamphetamine       I
 (7404).
3,4-Methyl-enedioxymethamphetamine (7405)..  I
4-Methoxyamphetamine (7411)................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
N-Ethyl-1-phenylcyclohexylamine (7455).....  I
Dihydromorphine (9145).....................  I
Normorphine (9313).........................  I
Acetylmethadol (9601)......................  I
Alphacetylmethadol Except Levo-              I
 Alphacetylmethadol (9603).
Normethadone (9635)........................  I
3-Methylfentanyl (9813)....................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
1-Phenylcyclohexylamine (7460).............  II
Phencyclidine (7471).......................  II
Phenylacetone (8501).......................  II
1-Piper-idinocyclohexanecarbonitrile (8603)  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Ethylmorphine (9190).......................  II
Hydrocodone (9193).........................  II
Isomethadone (9226)........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II
Levo-Alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The firm plans to manufacture small quantities of the listed 
controlled substances to produce standards for analytical laboratories.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than June 25, 2002.

    Dated: April 11, 2002.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 02-10305 Filed 4-25-02; 8:45 am]
BILLING CODE 4410-09-M